CT-P6: Clinical Trials

8 trials of CT-P6, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 recruiting, 1 terminated. 8 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 38Completed 6, Recruiting 1, Terminated 1

Follow CT-P6: new trials by email Literature Review of CT-P6 trials Research Report on CT-P6

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma
Phase 3RecruitingSWOG Cancer Research Network5622027-03-092026-10-13
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma
Phase 3TerminatedNational Cancer Institute (NCI)1902019-04-052026-05-29
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure - HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Phase 3CompletedNational Cancer Institute (NCI)3152014-02-182026-10-06
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 3CompletedNational Cancer Institute (NCI)2032011-02-142026-06-02
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Cyclophosphamide, Docetaxel, Doxorubicin - HER2/Neu Positive, Progesterone Receptor Positive
Phase 3CompletedNational Cancer Institute (NCI)32702011-02-082025-07-14
Demonstrate Efficacy and Safety of Metastatic Breast Cancer
CT-P6, Herceptin, Paclitaxel - Metastatic Breast Cancer
Phase 3CompletedCelltrion4752010-06-012025-02-11
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel - Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Phase 3CompletedNational Cancer Institute (NCI)3052009-02-242026-08-12
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation - Breast Ductal Carcinoma In Situ
Phase 3CompletedNational Cancer Institute (NCI)20142008-12-102025-06-12

Conditions studied

Breast Neoplasms (5)  ·  Adenocarcinoma Of Esophagus (1)  ·  Breast Neoplasms, Male (1)  ·  Carcinoma, Intraductal, Noninfiltrating (1)  ·  Esophageal Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (6)  ·  Celltrion (1)  ·  SWOG Cancer Research Network (1)

Countries

United States (7)  ·  Puerto Rico (4)  ·  Canada (3)  ·  South Korea (2)  ·  Ireland (1)

Top investigators

Charles E Geyer (1)  ·  Howard P Safran (1)  ·  Investigational Site (1)  ·  Lisa A Carey (1)  ·  Louis Fehrenbacher (1)  ·  Mariya Rozenblit (1)  ·  Melody A Cobleigh (1)  ·  Mothaffar F Rimawi (1)

Results publications

PMID 23984897, PMID 26527775, PMID 31821109, PMID 33095682, PMID 33739848, PMID 35038433, PMID 40170372, PMID 40480221

NIH funding

U10CA180868 (5), U10CA012027 (3), U10CA021661 (1), U10CA031946 (1), U10CA180821 (1), U10CA180830 (1), U10CA180888 (1)